Overview

A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder

Status:
Completed
Trial end date:
2015-01-08
Target enrollment:
Participant gender:
Summary
A study to compare the change in symptom severity in participants with schizophrenia or related psychotic disorder when treated with GWP42003 or placebo in conjunction with existing anti-psychotic therapy over a period of six weeks.
Phase:
Phase 2
Details
Lead Sponsor:
GW Research Ltd
Treatments:
Cannabidiol